Search Results
Showing Results for anti-VEGF
Susvimo® (ranibizumab injection) has become the first FDA-approved continuous delivery system for diabetic retinopathy (DR), reducing treatment frequency to once every nine months.1 The approval is based on the positive results of the phase III Pavilion study, showing significant improvement in disease severity.
On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov ...
The EURETINA 2024 Congress, held in Barcelona from September 19-22, brought together leading experts in ophthalmology to share the latest research and innovative treatments for retinal diseases. Among the highlights were several late-breaking abstracts that showcased promising advances in therapeutics for conditions such as retinopathy of prematurity (ROP), diabetic retinopathy (DR) and age-related macular degeneration (AMD). These studies not only demonstrated the efficacy and safety of novel treatment options but also addressed critical unmet needs in reducing patient burden and improving long-term outcomes.
Age-related macular degeneration (AMD) is a chronic deterioration and dysfunction of the outer retinal tissue and Bruch’s membrane (BrM). It is the leading cause of vision loss in people older than 60 years and is estimated to affect 288 million people ...
Contrast sensitivity (CS), which is an important element of functional vision, helps in differentiating an object from its background. CS affects several aspects of vision, such as acuity, dark adaptation, visual field, motion detection and pattern recognition.1 A decline in ...
Neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME) are two leading causes of visual impairment and blindness in the USA.1,2 Faricimab is the first bispecific antibody approved by the US Food and Drug Administration in ophthalmology and was ...
Retinal pharmacotherapy encompasses various drug delivery routes that offer potential avenues for effective treatment (Figure 1). Among these, intravitreal injections have emerged as the predominant method employed in clinical practice.1 They have established themselves as the primary approach for administering anti-vascular ...
Age-related macular degeneration (AMD) is a progressive eye condition that affects millions of people worldwide and poses a significant threat to vision in individuals over the age of 50.1 Of the two types of AMD, wet AMD, which is characterized by ...
The term ‘artificial intelligence’ was coined by a group of scientists during a workshop known as the “Dartmouth Summer Research Project on Artificial Intelligence” in 1956.1 The concept was based on the idea that “intelligent human behavior consisted in processes that ...
Faricimab inhibits both angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways which may extend treatment durability beyond current anti-VEGF therapies for diabetic macular edema (DME). It was a pleasure to speak with Dr Jennifer Lim (University of Illinois ...
Diabetic macular edema is characterised by exudative fluid accumulation in the macula and is the most common form of sight-threatening retinopathy in people with diabetes affecting one in 15 people with diabetes. Intraocular pharmacotherapy with anti-VEGF agents is the standard of ...
The CANDELA trial (NCT04126317) was a phase II, randomized, single-masked, open-label, clinical trial that assessed the safety and efficacy of aflibercept 8 mg versus the standard dose of 2 mg in patients with neovascular age-related macular degeneration (nAMD). It was a pleasure ...
Neovascular age-related macular degeneration (nAMD) is an advanced form of macular degeneration that historically has accounted for the majority of vision loss related to AMD. Current treatment consists of injecting inhibitors of vascular endothelial growth factor (VEGF) into the vitreous ...
The YOSEMITE/RHINE (NCT03622580/NCT03622593) trials were double-masked, active comparator–controlled, phase 3 trials investigating the efficacy, safety, and durability of faricimab 6.0 mg versus aflibercept 2.0 mg in patients with diabetic macular edema (DME). It was a pleasure to speak with Dr ...
Diabetic macular edema is characterised by exudative fluid accumulation in the macula and is the most common form of sight-threatening retinopathy in people with diabetes affecting one in 15 people with diabetes. Intraocular pharmacotherapy with anti-VEGF agents is the standard of ...
With the introduction of monoclonal antibody inhibitors for all isoforms of vascular endothelial growth factor (VEGF)-A, which were first presented in September 2005 with off-label use of bevacizumab, significant anatomical and visual improvements for neovascular age-related macular degeneration (nAMD) became ...
Identifying treatments that prevent diabetic retinopathy progression is a priority in current research. Patients with non-proliferative retinopathy currently have limited treatment options to prevent the progression of retinopathy and loss of vision, and therapies such as anti-vascular endothelial growth factor (...
Corticosteroids are the best choice for treating various ocular conditions affecting the anterior and posterior segments of the eye.1 Currently, different routes are available for ocular administration of corticosteroids. Topical application to the eye is the route of choice when ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
